Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of saponins in the preparing process of coxsackie virus resisting medicine

A drug and virus technology, applied in antiviral agents, medical preparations containing active ingredients, drug combinations, etc., can solve the problems of unreported pharmacological effects of monomer components

Inactive Publication Date: 2007-04-18
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Timosaponin A III The pharmacological effects of the monomer components have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of saponins in the preparing process of coxsackie virus resisting medicine
  • Application of saponins in the preparing process of coxsackie virus resisting medicine
  • Application of saponins in the preparing process of coxsackie virus resisting medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1: Drug of the present invention is to the impact test (in vivo) of viral myocarditis mouse mortality

[0031] 34 Balb / c mice were randomly divided into 3 groups.

[0032] Normal control group: 6 rats, neither the medicine of the present invention nor virus inoculation, but only an equal amount of distilled water.

[0033] Virus control group: 14 rats, each intraperitoneally inoculated with 0.1ml CVB 3 Virus fluid (TCID 50 =10 -7.5 , 10 5 double dilution).

[0034] Administration group: 14 rats, inoculated with CVB in the same way as above 3 Virus liquid, on the same day, was given the drug of the present invention by intragastric administration at 0.15mmol / kg·d for 7 consecutive days and observed until the 15th day.

[0035] Observe and record the animal's mental state, diet, coat color and death during the dosing (feeding) period.

[0036] Result: the medicine of the present invention can significantly reduce the 3 The mortality rate of mice with vi...

Embodiment 2

[0039] Embodiment 2: the influence test (in vivo) of medicine of the present invention on viral myocarditis mouse cardiac index

[0040] The grouping and dosage of Balb / c mice were the same as in Example 1. After 7 consecutive days of administration, all mice were dissected on the 15th day of observation. The mice were weighed before dissection, and their hearts were weighed after dissection.

[0041] Cardiac index = heart weight / body weight

[0042] When an animal is infected with a virus, its food intake decreases and its body weight decreases, but the heart becomes enlarged, fibrosis and heavier. Therefore, the cardiac index can be used to measure the degree of heart disease. The greater the cardiac index, the more serious the heart disease.

[0043] Result: the medicine of the present invention can significantly reduce the 3 See Table 2 for the heart index of mice with viral myocarditis caused by viruses.

[0044] group

[0045] Note: compared with the admi...

Embodiment 3

[0046] Embodiment 3: the influence test (in vivo) of medicine of the present invention to viral myocarditis mouse pathological section

[0047] The grouping and dosage of Balb / c mice were the same as in Example 1. After 7 days of administration, until the 15th day of observation, the mouse heart was fixed in formalin after dissection, and pathological sections were made. Myocardial inflammatory cell infiltration and myocardial fiber necrosis were observed under a microscope. Observe 5 visual fields for each specimen, record 0-25% lesion in each visual field as 1, 25%-50% as 2, 50%-75% as 3, 75%-100% as 4, if there is no lesion It is recorded as 0.

[0048] Experimental result shows, medicine of the present invention can effectively improve the effect caused by Coxsackie B. 3 The degree of lesion in mouse heart caused by virus.

[0049] group

[0050] Note: Using non-parametric statistical test, comparing the drug treatment group with the virus group, *P<0.05

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the medical use of Timosaponin a-III, wherein the Timosaponin a-III is extracted and isolated from the Chinese medicinal herb anemarrhena rhizome as the active constituent with the structural formula disclosed in the specification, medical experiment has proved that the Timosaponin a-III can suppress Coxsackie Group B Virus and treat virus cardiomyopathy.

Description

technical field [0001] The invention relates to a saponin active ingredient extracted and separated from the traditional Chinese medicine Anemarrhena, which has been proved by pharmacological tests to significantly inhibit Coxsackie Group B Virus (Coxsackie Group B Virus) and treat viral myocarditis. The active ingredient timosaponin A extracted from III , which can be used in the preparation of anti-Coxsackie virus drugs. Background technique [0002] Coxsackie virus can cause a variety of diseases, such as Coxsackie B virus mainly causes viral myocarditis. Viral myocarditis is a common clinical disease with degeneration and necrosis of myocardial cells and inflammatory cell infiltration as the main pathological changes. It occurs frequently in children and adolescents and seriously endangers human health. [0003] At present, the main method of Western medicine clinical treatment of viral myocarditis is to use common antiviral drugs, immunosuppressants, interferon and ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P31/14A61P9/00
Inventor 黄成钢朱海燕张媛媛张振秋王新亮施松
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com